Tags

Type your tag names separated by a space and hit enter

Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study.

Abstract

AIM

To assess the value of long-chain omega-3 fatty acids (FAs) supplementation in addition to amino-salicylic-acid (5-ASA) in pediatric patients with Crohn's disease (CD).

METHODS

Thirty-eight patients (20 males and 18 females, mean age 10.13 years, range 5-16 years) with CD in remission were randomized into two groups and treated for 12 mo. Group I (18 patients) received 5-ASA (50 mg/kg/d)+ omega-3 FAs as triglycerides in gastro-resistant capsules, 3 g/d (eicosapentanoic acid, EPA, 400 mg/g, docosahexaenoic acid, DHA, 200 mg/g). Group II (20 patients) received 5-ASA (50 mg/kg/d)+olive oil placebo capsules. Patients were evaluated for fatty acid incorporation in red blood cell membranes by gas chromatography at baseline 6 and 12 mo after the treatment.

RESULTS

The number of patients who relapsed at 1 year was significantly lower in group I than in group II (P<0.001). Patients in group I had a significant increase in the incorporation of EPA and DHA (P<0.001) and a decrease in the presence of arachidonic acids.

CONCLUSION

Enteric-coated omega-3 FAs in addition to treatment with 5-ASA are effective in maintaining remission of pediatric CD.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Pediatric Department, University of Messina, Italy. romanoc@unime.it

    , , ,

    Source

    World journal of gastroenterology 11:45 2005 Dec 07 pg 7118-21

    MeSH

    Adolescent
    Anti-Inflammatory Agents, Non-Steroidal
    Child
    Child, Preschool
    Crohn Disease
    Double-Blind Method
    Erythrocyte Membrane
    Fatty Acids, Omega-3
    Female
    Humans
    Male
    Mesalamine

    Pub Type(s)

    Journal Article
    Multicenter Study
    Randomized Controlled Trial

    Language

    eng

    PubMed ID

    16437657

    Citation

    Romano, C, et al. "Usefulness of Omega-3 Fatty Acid Supplementation in Addition to Mesalazine in Maintaining Remission in Pediatric Crohn's Disease: a Double-blind, Randomized, Placebo-controlled Study." World Journal of Gastroenterology, vol. 11, no. 45, 2005, pp. 7118-21.
    Romano C, Cucchiara S, Barabino A, et al. Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study. World J Gastroenterol. 2005;11(45):7118-21.
    Romano, C., Cucchiara, S., Barabino, A., Annese, V., & Sferlazzas, C. (2005). Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study. World Journal of Gastroenterology, 11(45), pp. 7118-21.
    Romano C, et al. Usefulness of Omega-3 Fatty Acid Supplementation in Addition to Mesalazine in Maintaining Remission in Pediatric Crohn's Disease: a Double-blind, Randomized, Placebo-controlled Study. World J Gastroenterol. 2005 Dec 7;11(45):7118-21. PubMed PMID: 16437657.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study. AU - Romano,C, AU - Cucchiara,S, AU - Barabino,A, AU - Annese,V, AU - Sferlazzas,C, PY - 2006/1/27/pubmed PY - 2006/3/21/medline PY - 2006/1/27/entrez SP - 7118 EP - 21 JF - World journal of gastroenterology JO - World J. Gastroenterol. VL - 11 IS - 45 N2 - AIM: To assess the value of long-chain omega-3 fatty acids (FAs) supplementation in addition to amino-salicylic-acid (5-ASA) in pediatric patients with Crohn's disease (CD). METHODS: Thirty-eight patients (20 males and 18 females, mean age 10.13 years, range 5-16 years) with CD in remission were randomized into two groups and treated for 12 mo. Group I (18 patients) received 5-ASA (50 mg/kg/d)+ omega-3 FAs as triglycerides in gastro-resistant capsules, 3 g/d (eicosapentanoic acid, EPA, 400 mg/g, docosahexaenoic acid, DHA, 200 mg/g). Group II (20 patients) received 5-ASA (50 mg/kg/d)+olive oil placebo capsules. Patients were evaluated for fatty acid incorporation in red blood cell membranes by gas chromatography at baseline 6 and 12 mo after the treatment. RESULTS: The number of patients who relapsed at 1 year was significantly lower in group I than in group II (P<0.001). Patients in group I had a significant increase in the incorporation of EPA and DHA (P<0.001) and a decrease in the presence of arachidonic acids. CONCLUSION: Enteric-coated omega-3 FAs in addition to treatment with 5-ASA are effective in maintaining remission of pediatric CD. SN - 1007-9327 UR - https://www.unboundmedicine.com/medline/citation/16437657/full_citation L2 - http://www.wjgnet.com/1007-9327/full/v11/i45/7118.htm DB - PRIME DP - Unbound Medicine ER -